Financial Results, Conference Calls Schedules, and Outlook- Research Report on Spectrum, Magellan, Insmed, GenMark, and Envision
NEW YORK, November 18, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), Magellan Health Services Inc. (NASDAQ: MGLN), Insmed Incorporated (NASDAQ: INSM), GenMark Diagnostics, Inc. (NASDAQ: GNMK), and Envision Healthcare Holdings, Inc. (NYSE: EVHC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Spectrum Pharmaceuticals, Inc. Research Report
On November 12, 2013, Spectrum Pharmaceuticals, Inc. (Spectrum) reported Q3 2013 financial results. In Q3 2013, the Company's GAAP consolidated revenues totaled $42.4 million, down 38.5% YoY. Q3 2013 net loss was $7.8 million, or $0.13 per diluted share, compared with net income of $21.5 million, or $0.33 per diluted share, in Q3 2012. "We are looking forward to filing the NDA for Belinostat before the end of this year and expect to bring this important treatment option to patients next year. We anticipate topline data for Captisol-enabled Melphalan's pivotal trial to be available in the second quarter of 2014, and to file an NDA soon thereafter. Further, SPI-2012, our long-acting, proprietary conjugated GCSF, is progressing well and could have a significant impact on our long-term growth. We remain focused on executing our long-term strategy and continue to add assets to further diversify our portfolio," said Rajesh C. Shrotriya, MD, Chairman, CEO and President of Spectrum. The Full Research Report on Spectrum Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/d344_SPPI
Magellan Health Services, Inc. Research Report
On November 12, 2013, Magellan Health Services, Inc. (Magellan) announced that it will release its FY2014 financial guidance on December 17, 2013. On the same day, the Company's CEO Barry M. Smith will host a conference call at 10:00 a.m. ET, while the press release on the Company's guidance will be issued at approximately 6:30 a.m. ET. The Full Research Report on Magellan Health Services, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/4b85_MGLN
Insmed Incorporated Research Report
On November 5, 2013, Insmed Incorporated (Insmed) reported Q3 2013 financial results. In Q3 2013, the Company reported a net loss of $17.3 million, or $0.46 per diluted share, compared with net loss of $9.4 million, or $0.38 per diluted share, in Q3 2012. "We continue work to build Insmed into a world-class biopharmaceutical company. Importantly, our successful financing in July with top-tier institutional investors provides us with the financial resources to advance ARIKACE for NTM lung disease and Pseudomonas aeruginosa lung infections in cystic fibrosis (CF) patients to important data readouts and regulatory filings, and to build our infrastructure to support clinical and commercial objectives," said Will Lewis, President and CEO of Insmed. The Full Research Report on Insmed Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/9c5b_INSM
GenMark Diagnostics, Inc. Research Report
On November 12, 2013, GenMark Diagnostics, Inc. (GenMark) reported Q3 2013 financial results. In Q3 2013, revenues were $4.6 million, down 11.8% YoY due to lack of purchases from Natural Molecular Testing Corporation (NMTC) during the quarter, offset by significant growth from other customers. Q3 2013 net loss was $10.8 million, or $0.30 loss per diluted share, compared with net loss of $6.3 million, or $0.20 loss per diluted share, in Q3 2012. "Our base business, which excludes NMTC, demonstrated impressive revenue growth on both a year-over-year and sequential basis, growing by 159% in the third quarter of 2013 compared with the third quarter of 2012, and growing approximately 21% quarter-over-quarter ahead of the flu season. We believe the significant growth of our base business confirms the increasing implementation of our eSensor technology across a growing customer base and validates its unique value proposition in advance of releasing our sample-to-answer NexGen system," said Hany Massarany, President and CEO of GenMark. The Full Research Report on GenMark Diagnostics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/a428_GNMK
Envision Healthcare Holdings, Inc. Research Report
On November 13, 2013, Envision Healthcare Holdings, Inc. (Envision) reported Q3 2013 financial results. In Q3 2013, the Company's net revenue increased 16.5% YoY to $955.9 million. Q3 2013 net loss was $7.7 million, or $0.05 loss per diluted share, compared with net income of $15.2 million, or $0.11 per diluted share, in Q3 2012. "During our first quarter as a public company we demonstrated exceptional revenue and Adjusted EBITDA growth. Customer demand for our differentiated services and the implementation of our market-centric strategies drove an increased level of contract starts and organic growth. Furthermore, our initial public offering provides us with additional sources of liquidity to capitalize on market acquisitions and development opportunities," said William A. Sanger, CEO of Envision. The Full Research Report on Envision Healthcare Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/4b31_EVHC
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented byAnanya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
Share this article